About Inventiva S.A.
https://www.inventivapharma.comInventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH.
CEO
Andrew Obenshain
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
YIHENG CAPITAL MANAGEMENT, L.P.
Shares:2.64M
Value:$15.82M
NEA MANAGEMENT COMPANY, LLC
Shares:1.46M
Value:$8.75M
BVF INC/IL
Shares:686.04K
Value:$4.1M
Summary
Showing Top 3 of 16
About Inventiva S.A.
https://www.inventivapharma.comInventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $4.45M ▼ | $59.55M ▲ | $-175.88M ▼ | -3.95K% ▼ | $-1.62 ▲ | $-165.84M ▼ |
| Q4-2024 | $6.46M ▲ | $52.3M ▼ | $-135.18M ▼ | -2.09K% ▼ | $-2.6 ▼ | $-114.71M ▼ |
| Q2-2024 | $2.73M ▼ | $54.46M ▼ | $-49.03M ▲ | -1.79K% ▼ | $-0.94 ▲ | $-51.82M ▼ |
| Q4-2023 | $16.54M ▲ | $63.69M ▲ | $-55.16M ▲ | -333.46% ▲ | $-1.13 ▲ | $-47.98M ▲ |
| Q2-2023 | $6.62M | $60.06M | $-55.27M | -834.63% | $-1.31 | $-53.86M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $122.08M ▲ | $178.52M ▲ | $187.87M ▼ | $-9.35M ▲ |
| Q4-2024 | $96.56M ▲ | $118.97M ▲ | $225.61M ▲ | $-106.65M ▼ |
| Q2-2024 | $10.44M ▼ | $39.43M ▼ | $118.49M ▲ | $-79.06M ▼ |
| Q4-2023 | $27.34M ▼ | $69.56M ▼ | $101.59M ▲ | $-32.03M ▼ |
| Q2-2023 | $31.29M | $70.82M | $78.49M | $-7.67M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-175.88M ▼ | $-53.89M ▼ | $-24.8M ▼ | $104.95M ▼ | $25.51M ▼ | $-53.95M ▼ |
| Q4-2024 | $-135.18M ▼ | $-37.59M ▲ | $-167K ▼ | $123.02M ▲ | $96.56M ▲ | $-37.66M ▲ |
| Q2-2024 | $-49.03M ▲ | $-48.34M ▼ | $8.91M ▲ | $22.57M ▼ | $10.15M ▲ | $-48.6M ▼ |
| Q4-2023 | $-55.16M ▲ | $-36.38M ▲ | $-29K ▲ | $31.23M ▲ | $-4.32M ▲ | $-36.69M ▲ |
| Q2-2023 | $-55.27M | $-45.23M | $-7.7M | $-2.15M | $-55.5M | $-45.46M |
CEO
Andrew Obenshain
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
YIHENG CAPITAL MANAGEMENT, L.P.
Shares:2.64M
Value:$15.82M
NEA MANAGEMENT COMPANY, LLC
Shares:1.46M
Value:$8.75M
BVF INC/IL
Shares:686.04K
Value:$4.1M
Summary
Showing Top 3 of 16